Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Research & Development (2020 - 2025)

Silo Pharma's Research & Development history spans 6 years, with the latest figure at $543615.0 for Q3 2025.

  • For Q3 2025, Research & Development rose 5.04% year-over-year to $543615.0; the TTM value through Sep 2025 reached $2.9 million, up 87.19%, while the annual FY2024 figure was $2.4 million, 180.22% up from the prior year.
  • Research & Development for Q3 2025 was $543615.0 at Silo Pharma, down from $717247.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.1 million in Q4 2024 and bottomed at -$546074.0 in Q4 2022.
  • The 5-year median for Research & Development is $202913.0 (2023), against an average of $265657.1.
  • The largest YoY upside for Research & Development was 7468.61% in 2021 against a maximum downside of 545.89% in 2021.
  • A 5-year view of Research & Development shows it stood at -$177225.0 in 2021, then crashed by 208.12% to -$546074.0 in 2022, then surged by 161.71% to $336965.0 in 2023, then soared by 219.24% to $1.1 million in 2024, then crashed by 49.46% to $543615.0 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Research & Development are $543615.0 (Q3 2025), $717247.0 (Q2 2025), and $593962.0 (Q1 2025).